The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC.
 
Jose Carlos Benitez
No Relationships to Disclose
 
Marie Eve Boucher
Consulting or Advisory Role - AstraZeneca
 
Eric Dansin
No Relationships to Disclose
 
Mallorie Kerjouan
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Eric Pichon
No Relationships to Disclose
 
Francois Thillays
No Relationships to Disclose
 
Pierre-Emmanuel Falcoz
No Relationships to Disclose
 
Benoit Roch
No Relationships to Disclose
 
Youssef Oulkhouir
Honoraria - AstraZeneca; MSD Oncology; Roche
Travel, Accommodations, Expenses - Pfizer
 
Calcagno Fabien
No Relationships to Disclose
 
Luc Thiberville
No Relationships to Disclose
 
Christelle Clément Duchene
No Relationships to Disclose
 
Franck Morin
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Pascale Missy
No Relationships to Disclose
 
Pascal Alexandre Thomas
No Relationships to Disclose
 
Jean-Michel Maury
No Relationships to Disclose
 
Thierry Molina
No Relationships to Disclose
 
Nicolas Girard
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pharmamar; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Roche
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst); Tolero Pharmaceuticals (Inst)